miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 16, 2026

Is Shell (LSE:SHEL) Still Attractive After A 43% One-Year Share Price Gain?

View original at finance.yahoo.com
“The latest twelve month free cash flow is about US$23.94b.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Shell scores 4 out of 6 on Simply Wall St's valuation checks, suggesting it screens as undervalued on most, but not all, metrics

    60% confidence

  • Analyst forecasts and Simply Wall St extrapolations indicate free cash flow of US$27.30b in 2030

    60% confidence

  • DCF analysis suggests Shell is undervalued by 54.0% with an estimated intrinsic value of US$72.77 per share compared to current price of £33.46

    60% confidence

Data points we hold from this source

Shell plc · stock return 1w-1.6 percent
Shell plc · stock return ytd21.3 percent
Shell plc · stock return 1y43.0 percent
Shell plc · stock return 1m-2.0 percent
Shell plc · free cash flow23.94 USD
Shell plc · free cash flow forecast27.30 USD
Shell plc · valuation score4 out_of_6
Shell plc · intrinsic value dcf72.77 USD
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Is Shell (LSE:SHEL) Still Attractive After A 43% One-Year Share Price Gain? — Source | Via News | es.VIA.NEWS